Using artificial intelligence to improve breast cancer screening in Córdoba
New Strategies Based on Artificial Intelligence in Breast Cancer Screening Programs in Córdoba With Digital Mammography and Digital Breast Tomosynthesis. A Prospective Evaluation.
This study tests if using artificial intelligence can make breast cancer screenings easier and faster for women aged 50 to 69 without missing important detections.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 27000 (estimated) |
| Ages | 50 Years to 69 Years |
| Sex | Female |
| Sponsor | Maimónides Biomedical Research Institute of Córdoba Academic / other |
| Locations | 1 site (Córdoba) |
| Trial ID | NCT04949776 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of artificial intelligence software, Transpara®, in breast cancer screening programs. It aims to determine if AI-assisted reading strategies can reduce the workload of screening by over 50% while maintaining detection rates and recall rates. The study involves women aged 50 to 69 who are part of the Breast Cancer Early Detection Program at Reina Sofía University Hospital. Participants will undergo mammograms with the AI software to assess its impact on screening efficiency.
Who should consider this trial
Good fit: Ideal candidates are women aged 50 to 69 participating in the Breast Cancer Early Detection Program at Reina Sofía University Hospital.
Not a fit: Patients with breast prostheses or those showing symptoms of suspected breast cancer may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could streamline breast cancer screening processes and improve early detection rates.
How similar studies have performed: Other studies have shown promise in using AI for medical imaging, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any woman between the ages of 50 and 69, from the hospital area of the Reina Sofía University Hospital, invited to the Breast Cancer Early Detection Program, summoned in rooms 2024 and 2001 and who agrees to participate in the study by signing the consent informed. * Women studied in the program in the set period and who have previously participated. * Women who are studied in the program for the first time in the set period. Exclusion Criteria: * Women invited to the program who do not agree to enter the research study by signing the informed consent. * Women with breast prostheses. * Women with symptoms or signs of suspected breast cancer.
Where this trial is running
Córdoba
- Hospital Universitario Reina Sofia — Córdoba, Spain (Recruiting)
Study contacts
- Principal investigator: Esperanza Elias Cabot, MD — Hospital Universitario Reina Sofia de Cordoba
- Study coordinator: Esperanza Elias Cabot, MD
- Email: eeliascabot@gmail.com
- Phone: 0034957213700
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.